Table 5 Evaluation of proposed framework by using 10-fold cross validation results.
Type/Fold | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---|---|---|---|---|---|---|---|---|---|---|
Healthy (%) | 93.94 | 97.89 | 95.92 | 97.59 | 96.93 | 93.94 | 97.21 | 97.89 | 94.81 | 93.94 |
Anterior (%) | 97.93 | 94.12 | 94.79 | 94.45 | 93.51 | 93.94 | 97.34 | 93.12 | 94.69 | 97.79 |
Anteriolateral (%) | 93.94 | 97.34 | 93.94 | 93.12 | 94.69 | 97.79 | 93.94 | 95.92 | 97.59 | 96.93 |
Anterioseptal (%) | 93.84 | 93.95 | 93.94 | 93.9 | 93.95 | 93.93 | 93.92 | 93.97 | 93.89 | 93.95 |
Anterioseptal Lateral (%) | 94.69 | 97.79 | 93.94 | 97.89 | 95.92 | 97.59 | 97.21 | 97.89 | 94.81 | 93.94 |
Inferior (%) | 93.97 | 93.97 | 97.89 | 95.92 | 93.95 | 93.97 | 93.95 | 93.93 | 93.95 | 93.97 |
Inferiolateral (%) | 93.95 | 93.92 | 93.97 | 93.93 | 93.94 | 97.88 | 93.95 | 93.94 | 93.97 | 93.93 |
Inferioposterior (%) | 97.89 | 95.92 | 97.59 | 96.93 | 93.94 | 97.21 | 95.94 | 97.49 | 96.94 | 95.87 |
Inferioposterior Lateral (%) | 97.68 | 95.45 | 93.94 | 95.92 | 97.59 | 96.93 | 92.95 | 96.94 | 93.94 | 94.39 |
Lateral (%) | 94.56 | 93.97 | 97.89 | 95.92 | 97.89 | 95.92 | 97.59 | 97.89 | 95.92 | 97.59 |
Posterior (%) | 97.89 | 95.92 | 97.59 | 96.93 | 93.94 | 97.21 | 94.12 | 94.45 | 94.39 | 94.79 |
Posteriolateral (%) | 93.97 | 93.95 | 97.89 | 95.92 | 97.59 | 96.93 | 95.92 | 96.93 | 97.89 | 93.94 |
